Baseline | 12 months | |
BCVA LogMAR, mean (Snellen equivalent) | 0.81 (20/130) | 0.26 (20/36) |
IOP, mm Hg, mean±SD | 24.2±6.9 | 14.6±3.2 |
IOP >30 mm Hg, % | 10 | 0 |
IOP>20 mm Hg, % | 70 | 0 |
>2 lines drop in BCVA | – | 0% |
IOP-lowering drugs, mean, n | 1.3 | 0.5 |
Endothelial cell density, cells/mm2, mean±SD | 2619±228 | 2312±210 |
ECD <2000 cells/mm2, n | 0 | 0 |
– | 0 | |
>25% endothelial cell loss, n | – | 0 |
Inflammation, persistent (>1M) | – | 0 |
Inflammation, severe (grade 4+) | – | 0 |
Hyphema, persistent (>1M) | – | 0 |
Hyphema, severe (>3 mm) | – | 0 |
Corneal oedema, persistent (>1M) | – | 0 |
Stent migration | – | 0 |
Stent-corneal touch | – | 0 |
BCVA, Best Corrected Visual Acuity; ECD, Endothelial Cell Density; IOP, intraocular pressure.